IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Redox Biol (2018). Figure 4. IMD 0354|
|Incubation Time||3 weeks|
|Results||Notably, administration of IMD-0354 to rAAV2-LMP10-injected mice significantly blocked Ang II-induced increases in the central retinal thickness, vascular permeability and VEGF expression at both mRNA and protein levels compared with vehicle control.|
|Related IκB/IKK Products|
LY2409881 is a novel selective inhibitor of IKK2 with IC50 of 30 nM; IC50 for IKK1 and other common kinases is at least one log higher.
PS-1145 is a specific IKK inhibitor with IC50 of 88 nM.
Bardoxolone is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor.
Amlexanox is a specific inhibitor of IKKε and TBK1.
PHA-408 is a highly selective and ATP-competitive IKK-2 inhibitor with IC50 of 40 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.